B
NTLA icon

Bailard’s Intellia Therapeutics NTLA Stock Holding History

Bailard’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,300
Closed -$210K – 748
2021
Q2 		$210K Sell
1,300
-1,200
-48% -$93.4K 0.01% 665
2021
Q1 		$201K Sell
2,500
-59,800
-96% -$4.01M 0.01% 667
2020
Q4 		$3.39M Buy
62,300
+2,200
+4% +$79.9K 0.15% 118
2020
Q3 		$1.2M Hold
60,100
– – 0.06% 183
2020
Q2 		$1.26M Buy
+60,100
New +$1.02M 0.07% 179

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bailard's NTLA Position: Q3 2021 in Review

Bailard sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 1,300 shares — an estimated $210K sold.

Bailard first reported a position in NTLA in Q2 2020 and held it in 5 quarters. The position peaked at $3.39M in Q4 2020. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Bailard reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bailard sold 1,300 Intellia Therapeutics shares in Q3 2021, an estimated $210K.
  • Bailard first reported a position in Intellia Therapeutics in Q2 2020 and held it in 5 quarters.
  • Bailard's Intellia Therapeutics position peaked at $3.39M in Q4 2020.
  • 364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.